A Robust and Comprehensive Study of the Molecular and Genetic Basis of Neurodevelopmental Delay in a Sample of 3244 Patients, Evaluated by Exome Analysis in a Latin Population
Authors:
- Julian LamillaJLJulian Lamilla
- Taryn A. Castro-CuestaTCTaryn A. Castro-Cuesta
- Paula Rueda-GaitánPRPaula Rueda-Gaitán
- Laura Camila Rios PintoLPLaura Camila Rios Pinto
- Diego Alejandro Rodríguez GutiérrezDGDiego Alejandro Rodríguez Gutiérrez
- Yuri Natalia Sanchez RubioYRYuri Natalia Sanchez Rubio
- Carlos Estrada-SerratoCECarlos Estrada-Serrato
- Olga LondoñoOLOlga Londoño
- Cynthia RucinskiCRCynthia Rucinski
- Mauricio Arcos-BurgosMAMauricio Arcos-Burgos
- Mario Isaza-RugetMIMario Isaza-Ruget
- Juan Javier López RiveraJRJuan Javier López Rivera
Open Access
- 5 February 2025
- journal article
- research article
- Published by MDPI AG in Diagnostics
- Vol. 15 (3) , 376
Abstract
Background and Objectives: Neurodevelopmental disorders (NDDs), including developmental delay (DD), autism spectrum disorder (ASD), intellectual disability (ID), attention-deficit/hyperactivity disorder (ADHD), and specific learning disorders, affect 15% of children and adolescents worldwide. Advances in next-generation sequencing, particularly whole exome sequencing (WES), have improved the understanding of NDD genetics. Methodology: This study analyzed 3244 patients undergoing WES (single, duo, trio analyses), with 1028 meeting inclusion criteria (67% male; aged 0–50 years). Results: Pathogenic (P) or likely pathogenic (LP) variants were identified in 190 patients, achieving a diagnostic yield of 13.4% (singleton), 14% (duo), and 21.2% (trio). A total of 207 P/LP variants were identified in NDD-associated genes: 38% were missense (48 de novo), 29% frameshift (26 de novo), 21% nonsense (14 de novo), 11% splicing site (14 de novo), and 1% inframe (1 de novo). De novo variants accounted for 49.8% of cases, with 86 novels de novo variants and 27 novel non de novo variants unreported in databases like ClinVar or scientific literature. Conclusions: This is the largest study on WES in Colombian children with NDDs and one of the largest in Latino populations. It highlights WES as a cost-effective first-tier diagnostic tool in low-income settings, reducing diagnostic timelines and improving clinical care. These findings underscore the feasibility of implementing WES in underserved populations and contribute significantly to understanding NDD genetics, identifying novel variants with potential for further research and clinical applications.Keywords
All Related Versions
This publication has 24 references indexed in Scilit:
- De novo variants underlying monogenic syndromes with intellectual disability in a neurodevelopmental cohort from IndiaEuropean Journal of Human Genetics, 2023
- A meta-analysis of genetic effects associated with neurodevelopmental disorders and co-occurring conditionsNature Human Behaviour, 2023
- Disruption of the gene regulatory programme in neurodevelopmental disordersBiochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, 2022
- Comparison of the diagnostic yield of aCGH and genome-wide sequencing across different neurodevelopmental disordersnpj Genomic Medicine, 2021
- Loss-of-function Mutations of CUL3, a High Confidence Gene for Psychiatric Disorders, Lead to Aberrant Neurodevelopment In Human Induced Pluripotent Stem CellsNeuroscience, 2020
- Large-Scale Exome Sequencing Study Implicates Both Developmental and Functional Changes in the Neurobiology of AutismCell, 2020
- Meta-analysis and multidisciplinary consensus statement: exome sequencing is a first-tier clinical diagnostic test for individuals with neurodevelopmental disordersGenetics in Medicine, 2019
- Whole-exome sequencing in intellectual disability; cost before and after a diagnosisEuropean Journal of Human Genetics, 2018
- Effectiveness of whole-exome sequencing and costs of the traditional diagnostic trajectory in children with intellectual disabilityGenetics in Medicine, 2016
- SHANK3 as an autism spectrum disorder-associated geneBrain and Development, 2013